GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. Its stock price reflects the growth of screening volumes and the potential of its diagnostic platforms for early detection of other cancers.
Share prices of companies in the market segment - Medanalysis
Exact Sciences operates in the molecular diagnostics segment, offering cancer tests such as Cologuard. We classify it as a medical analysis. The chart below shows the overall dynamics of this sector, driven by growing demand for early diagnosis.
Broad Market Index - GURU.Markets
Exact Sciences is a leader in early cancer diagnostics, known for its noninvasive colorectal cancer screening test, Cologuard. As a significant biotech company, it is included in the GURU.Markets index. The chart below helps you assess its performance relative to the overall US market.
Change in the price of a company, segment, and market as a whole per day
EXAS - Daily change in the company's share price Exact Sciences
For Exact Sciences, a leader in early cancer diagnostics, daily price changes are a measure of reaction to biotech news. While the chart of these fluctuations isn't particularly spectacular, they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
Exact Sciences Corporation is a leader in early cancer diagnostics. This chart highlights the high volatility of the biotech sector. A comparison with EXAS, whose success depends on the implementation of its tests (Cologuard), helps to understand its unique risks compared to pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Exact Sciences is a leader in early cancer diagnostics, known for its Cologuard colorectal cancer screening test. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below shows the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Exact Sciences
Exact Sciences, the company behind the popular Cologuard cancer test, has been expanding its oncology diagnostics portfolio over the past year. The year-over-year stock performance, shown in the chart, reflects the market's appreciation of this strategy and the potential of its new products.
Annual dynamics of market capitalization of the market segment - Medanalysis
Exact Sciences Corporation is a leader in early cancer diagnostics, known for its Cologuard colorectal cancer screening test. Its future depends on the success of new diagnostic tests. The chart below shows how its innovations and market expansion efforts are impacting its performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exact Sciences is a cancer diagnostics company best known for its noninvasive colon cancer test, Cologuard. The company's growth is driven by the increase in screenings. Its stock price reflects the success of its tests' commercialization.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Exact Sciences
Exact Sciences, a molecular diagnostics company, is changing approaches to cancer detection. The monthly fluctuations on the chart reflect testing volumes for its flagship colorectal cancer screening product, Cologuard, and news about the development of new tests for the early detection of other oncological diseases.
Monthly dynamics of market capitalization of the market segment - Medanalysis
This chart reflects the dynamics of the molecular diagnostics sector. For Exact Sciences, a pioneer in this field, it's the backdrop. Its movements reflect the commercial success of its Cologuard cancer test and expectations for its extensive pipeline of new diagnostic tests.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exact Sciences is the company behind the popular noninvasive colon cancer test Cologuard. Its history is one of growth and innovation in diagnostics. Against the backdrop of market trends shown in the chart, Exact Sciences' performance is primarily determined by the pace of adoption of its tests and its success in developing new diagnostic products for early cancer detection.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Exact Sciences
Exact Sciences is a molecular diagnostics company known for its Cologuard cancer test. Weekly stock performance is heavily influenced by news about the volume of tests conducted, insurance coverage decisions, and data from new clinical trials.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company. Comparing its weekly performance with the medical devices sector reveals how the market views its cancer tests. Graáfico allows you to see how news about testing volumes or insurance company decisions influence its stock price movement independently of overall industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Exact Sciences, a diagnostics company, shares exist in a world of their own, far removed from macroeconomic news. Their performance is determined by testing volumes and insurance company decisions. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
EXAS - Market capitalization of the company Exact Sciences
Exact Sciences' market capitalization tells the story of how the market values the future of early cancer detection. The company's chart, known for its noninvasive colorectal cancer test, Cologuard, reflects both current sales and the high hopes for new diagnostic products. Its dynamics are a saga of investor faith in defeating cancer through early detection.
EXAS - Share of the company's market capitalization Exact Sciences within the market segment - Medanalysis
Exact Sciences is the company behind Cologuard, a noninvasive colorectal cancer screening test. Its stake in the medical diagnostics sector reflects the commercial success of this product and its confidence in its future developments. The chart below shows Exact Sciences' role in the early cancer detection revolution.
Market capitalization of the market segment - Medanalysis
Exact Sciences is the company behind Cologuard, a non-invasive colorectal cancer screening test. The chart below shows the overall market capitalization of the medical diagnostics sector. Its dynamics reflect the trend toward early disease detection and the healthcare system's willingness to pay for innovative and convenient tests.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a chart of a company changing the approach to cancer diagnostics. Exact Sciences has developed non-invasive tests, and its market cap is based on early disease detection. The chart illustrates the enormous potential and risks of biotech, where a single successful product can transform the entire industry.
Book value capitalization of the company, segment and market as a whole
EXAS - Book value capitalization of the company Exact Sciences
Exact Sciences' book value is derived from its high-tech laboratories, diagnostic equipment, and patents for early cancer detection tests. This represents scientific and material capital aimed at saving lives. The chart below shows how the company built this foundation through R&D and strategic acquisitions, such as the purchase of the developer of the Cologuard test.
EXAS - Share of the company's book capitalization Exact Sciences within the market segment - Medanalysis
Exact Sciences is a leader in cancer diagnostics, and its strength is concentrated in high-tech laboratories. The company's main asset is its massive, automated laboratory facilities capable of analyzing millions of tests. The chart shows the significant share of the physical laboratory infrastructure in its niche that the company controls.
Market segment balance sheet capitalization - Medanalysis
Exact Sciences, a diagnostics company, has a capital-intensive business. This requires the ownership of large, automated laboratories capable of processing hundreds of thousands of tests. The BCap_Seg chart for the medical equipment sector shows that leadership in diagnostics requires a significant resource base.
Book value of all companies included in the broad market index - GURU.Markets
Exact Sciences' capital isn't represented by factories in the classic sense, but by cutting-edge diagnostic laboratories and a portfolio of patents for early cancer detection tests. Its book value reflects its investments in science and high-tech equipment. The chart shows the material scale of this leader in medical diagnostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Exact Sciences
Exact Sciences' balance sheet is its labs and equipment. The colossal premium the market pays reflects the valuation of its revolutionary early cancer detection tests, such as Cologuard. The price chart reflects investors' belief that its technologies will transform medicine and capture a huge market.
Market to book capitalization ratio in a market segment - Medanalysis
Exact Sciences is known for its colon cancer screening test, Cologuard. The company's value is based almost entirely on its intellectual property, approved tests, and commercial infrastructure. The chart shows investors' high appreciation for its potential in medical diagnostics.
Market to book capitalization ratio for the market as a whole
Exact Sciences is a molecular diagnostics company known for its colon cancer test, Cologuard. Its value is derived from its intellectual property, patents, and the potential of new diagnostic tests. Its market valuation significantly exceeds its book value, reflecting the expectations of biotech investors.
Debts of the company, segment and market as a whole
EXAS - Company debts Exact Sciences
Exact Sciences, a molecular diagnostics company, is taking on debt to fund large-scale research, clinical trials, and the commercialization of its tests, like Cologuard. This chart shows how the company is betting big on the future of cancer diagnostics, using debt to finance its scientific and commercial growth.
Market segment debts - Medanalysis
Exact Sciences is the company behind the popular colon cancer test Cologuard. The molecular diagnostics industry requires massive investments in research, clinical trials, and marketing. Debt reflects the cost of bringing such innovative products to market and promoting them. This chart illustrates the company's financial strategy for achieving profitability.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Exact Sciences
Exact Sciences is a molecular diagnostics company known for its Cologuard cancer test. Developing and promoting such products requires significant investment. This chart shows how the company finances its operations. Debt levels are an indicator of the risk associated with dependence on the success of one or more key products.
Market segment debt to market segment book capitalization - Medanalysis
Exact Sciences is a pioneer in early cancer diagnostics, known for its Cologuard test. Bringing such innovative products to market and promoting them requires significant investment. The chart shows how the company's debt load, dedicated to research and marketing, compares to the overall market capitalization of the medical diagnostics sector.
Debt to book value of all companies in the market
Exact Sciences, a pioneer in cancer diagnostics, incurs significant R&D and marketing expenses. This chart allows us to assess the scale of these risky investments by comparing the company's debt to the total market capitalization of the entire stock market. This places the risks of biotech in a broader economic context.
P/E of the company, segment and market as a whole
P/E - Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer screening test, Cologuard. This chart shows investor sentiment toward its profitability. The metric's dynamics reflect the success of Cologuard's commercialization and market confidence in the potential of the company's other diagnostic tests.
P/E of the market segment - Medanalysis
Exact Sciences is a leader in cancer diagnostics, known for its Cologuard test. This chart shows the average valuation for the medical diagnostics sector. Comparisons help understand the premium the market places on Exact Sciences for its commercial success and the potential of its future testing portfolio.
P/E of the market as a whole
Exact Sciences is the company behind Cologuard, a noninvasive colon cancer screening test. It's a breakthrough technology in early diagnostics. This chart shows the overall risk appetite in biotech. Exact Sciences' valuation depends less on general sentiment than on specific metrics: the number of tests performed, insurance approvals, and the success of new developments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Exact Sciences
Exact Sciences is a company specializing in molecular cancer diagnostics, best known for its Cologuard colorectal cancer screening test. This chart illustrates market expectations for the widespread adoption of its tests. The trend reflects sales volume forecasts and the success of new diagnostic products.
%20P%2FE%20Exact%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Exact-Sciences&v=1772513565760 "Chart of the company's future (projected) P/E Exact Sciences")
Future (projected) P/E of the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. This chart shows profitability expectations for the sector. It helps understand whether investors believe in the potential of Cologuard and the company's other diagnostic tests to transform approaches to early cancer detection.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772513565772 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer screening test, Cologuard. This chart reflects overall profitability expectations. For a company changing approaches to early cancer detection, it demonstrates the market's willingness to invest in long-term healthcare innovation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513565799 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. The resulting revenue, illustrated by this chart, depends on the number of tests performed and insurance reimbursement. This trend demonstrates commercial success in advancing early cancer detection.
Profit of companies in the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colorectal cancer screening test, Cologuard. Its mission is the early detection of cancer. This chart reflects the potential and profitability of the medical diagnostics sector, where innovative tests like Cologuard have the potential to transform treatment standards.
Overall market profit
Exact Sciences is a company specializing in the development of early cancer diagnostic tests, including the well-known Cologuard. Demand for its products depends on insurance coverage and the willingness of people to undergo screening. Overall economic health, reflected in this graph, influences the stability of the healthcare system that ensures access to such tests.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its Cologuard colon cancer screening test. The earnings forecast you see here reflects analysts' expectations for increased testing and the success of new diagnostic products. This is a bet on preventative medicine and early cancer detection.
%20profit%20of%20the%20company%20Exact%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Exact-Sciences&v=1772513565851 "Graph of future (projected) profit of the company Exact Sciences")
Future (predicted) profit of companies in the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer screening test, Cologuard. Their goal is early cancer detection. This chart displays revenue projections for the medical analytics sector, allowing one to assess the commercial potential of Exact Sciences' diagnostic products relative to the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772513565873 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Exact Sciences is a company specializing in the development of tests for the early detection of cancer, particularly colon cancer. Demand for its products depends on the coverage of screening programs and the solvency of healthcare systems. This curve, reflecting the state of the economy, influences healthcare funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513565977 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Exact Sciences
Exact Sciences is the company behind Cologuard, a noninvasive colon cancer screening test. This chart shows how the market values its revenue, which is growing rapidly thanks to the test's widespread adoption. The high sales valuation reflects the potential of its diagnostic technologies for early cancer detection.
P/S market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its Cologuard test for noninvasive colorectal cancer screening. The company's revenue has grown as the number of tests performed and the product line expanded. This chart provides an overview of how the market views Exact Sciences' innovations in early cancer detection.
P/S of the market as a whole
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. Its revenue depends on the widespread adoption of its tests and insurance coverage. This chart helps assess the market's confidence in the potential of early detection companies and their future revenue projections.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Exact Sciences
Exact Sciences is the company behind Cologuard, a noninvasive colon cancer screening test. This chart shows how the market values the company relative to its future sales. It reflects investor expectations for the growth of Cologuard and the success of other diagnostic tests in development.
%20P%2FS%20Exact%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Exact-Sciences&v=1772513566040 "The graph of the company's future (projected) P/S Exact Sciences")
Future (projected) P/S of the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company offering early cancer detection tests, most notably the Cologuard colorectal cancer screening test. Its mission is to transform the approach to cancer diagnostics. This chart shows market expectations for future sales of its tests compared to other diagnostic companies.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772513566048 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Exact Sciences is a molecular diagnostics company best known for its colon cancer screening test, Cologuard. Its future revenue depends on the widespread adoption of its tests and the development of new ones. This general expectations chart for EXAS is not a direct driver. Demand is determined by demographics, physician recommendations, and insurance coverage.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513566049 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Exact Sciences
This chart illustrates a breakthrough in cancer diagnostics. For Exact Sciences, it reflects rapid growth driven by the widespread adoption of Cologuard®, their noninvasive colorectal cancer screening test. The success of this product is a key driver of the company's financial performance.
Sales of companies in the market segment - Medanalysis
Exact Sciences Corporation specializes in molecular cancer diagnostics. Its flagship product, Cologuard, is a noninvasive colorectal cancer screening test. Testing volume directly impacts revenue. This chart shows how a focus on early diagnosis and disease prevention is driving growth for Exact Sciences and the overall market.
Overall market sales
Exact Sciences is the company behind the popular Cologuard test for early detection of colorectal cancer. Its revenue reflects the growing demand for preventive medicine and non-invasive diagnostic methods. The company's business is a marker of important changes in the healthcare sector, which accounts for a significant portion of the overall economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer screening test, Cologuard. Future sales depend on the widespread adoption of this and other diagnostic tests. This chart reflects expected growth in the early cancer screening market.
%20sales%20of%20the%20company%20Exact%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Exact-Sciences&v=1772513566132 "Schedule of future (projected) sales of the company Exact Sciences")
Future (projected) sales of companies in the market segment - Medanalysis
Exact Sciences Corporation is a molecular diagnostics company best known for its Cologuard colon cancer test. This forecast for the medical analytics sector highlights the demand for early diagnostics. This chart illustrates how the shift toward preventative medicine is creating a huge market for the company's innovative tests.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772513566133 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Exact Sciences is a company specializing in the development of early cancer diagnostic tests, including the popular Cologuard test. Demand for its services depends on demographic trends and physician recommendations, rather than economic cycles. However, the overall economic situation, as reflected here, can impact insurance coverage and patient willingness to undergo screening tests.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513566134 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Exact Sciences
Exact Sciences, a molecular diagnostics company, uses this chart to illustrate the commercial success of its flagship product, Cologuard, a noninvasive colorectal cancer screening test. Profitability depends on testing volume, insurance reimbursement, and investment in the development of new diagnostic tests.
Market segment marginality - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer screening test, Cologuard. This chart shows the average profitability in the medical diagnostics sector. The uniqueness and widespread adoption of its flagship product enable the company to generate profitability above the industry average.
Market marginality as a whole
Exact Sciences Corporation is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. This chart shows average profitability. It illustrates how a breakthrough diagnostic product can transform the market, but achieving profitability requires significant investment in marketing and research.
Employees in the company, segment and market as a whole
Number of employees in the company Exact Sciences
Exact Sciences is a molecular diagnostics company best known for its Cologuard colon cancer screening test. The team's rapid growth, which can be seen in this chart, is a direct result of the test's commercial success and its active investment in developing new diagnostic products for early cancer detection.
Share of the company's employees Exact Sciences within the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colorectal cancer screening test, Cologuard. This chart illustrates its scientific and commercial scale. It reflects the significant share of Exact Sciences' scientists, lab technicians, and sales staff in the oncology diagnostics field.
Number of employees in the market segment - Medanalysis
Exact Sciences is the company behind Cologuard, a noninvasive colon cancer screening test. This chart illustrates the revolution in molecular diagnostics. The growth in the number of scientists, technicians, and sales staff is driven by the shift toward early disease diagnosis using advanced genetic testing.
Number of employees in the market as a whole
Exact Sciences is a company specializing in the development of early cancer detection tests, including the well-known Cologuard test. Demand for its services depends on the coverage of screening programs. Stable employment, as seen in this graph, means more people have access to health insurance that covers preventive screenings.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Exact Sciences (EXAS)
Exact Sciences revolutionized cancer diagnostics with its noninvasive colorectal cancer screening test, Cologuard. This chart illustrates the enormous value the market places on its research. Its high market cap per employee demonstrates that its team of scientists and technicians has created a product that could save millions of lives.
%20of%20the%20company%20Exact%20Sciences%20(EXAS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Exact-Sciences-EXAS&v=1772513566396 "Chart of market capitalization per employee (in thousands of dollars) of the company Exact Sciences (EXAS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. It's a business at the intersection of biotech and diagnostics. This chart shows the industry's average market capitalization per employee. It helps understand how the market values Exact Sciences' technology platform and its commercial success (Cologuard) per employee.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772513566465 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Exact Sciences is a molecular diagnostics company best known for its Cologuard colon cancer screening test. Its value is based on its unique technology and significant market potential. This chart illustrates how the market values a biotech company where scientific innovation creates significant value per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513566503 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Exact Sciences (EXAS)
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test (Cologuard). It's a business at the intersection of biotech and services. This chart shows how profitable their diagnostic platform is. It measures how much revenue each employee (lab technician, scientist, salesperson) generates from processing and selling tests.
%20Chart%20Exact%20Sciences%20(EXAS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Exact-Sciences-EXAS&v=1772513566515 "Company Profit Per Employee (in thousands of dollars) Chart Exact Sciences (EXAS)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Exact Sciences is a leader in molecular diagnostics (Cologuard). This chart shows the benchmark for Med-Analysis. The average profit per employee in this sector is a hybrid. The benchmark reflects both R&D (test development) and service (the operation of giant laboratories). It's a scalable but capital-intensive laboratory business.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772513566541 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. The business is built on science and technology. This chart shows how a unique, patented diagnostic product can generate significant revenue, ensuring high profitability per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513566550 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Exact Sciences (EXAS)
Exact Sciences is a molecular diagnostics company known for its colon cancer test, Cologuard. This chart shows the commercial potential of its products. The high revenue per employee reflects the high cost of diagnostic tests and the efficiency of its laboratory and commercial operations. This is an indicator of the successful monetization of science.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Exact-Sciences-EXAS&v=1772513566571 "Sales chart per company employee Exact Sciences (EXAS)")
Sales per employee in the market segment - Medanalysis
Exact Sciences is the company behind Cologuard, a noninvasive colon cancer screening test. It's a molecular diagnostics company. This metric reflects how effectively their labs, R&D, and sales teams generate revenue from each test. It helps assess the commercial success of their key product.
Sales per employee for the market as a whole
Exact Sciences is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. It's a research-intensive business. This chart shows how much revenue each employee (scientists, technicians, and marketers) generates. It reflects the commercial success of their flagship product and the efficiency of their labs, which process hundreds of thousands of tests.
Short shares by company, segment and market as a whole
Shares shorted by company Exact Sciences (EXAS)
Exact Sciences revolutionized cancer diagnostics with Cologuard, a noninvasive colon cancer test. This chart indicates bearish sentiment. Bearish sentiment may be concerned that Cologuard will face new, more accurate competition (such as blood tests) or that the company is overspending on marketing to promote its tests.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Exact-Sciences-EXAS&v=1772513566609 "Short Shares Chart for the Company Exact Sciences (EXAS)")
Shares shorted by market segment - Medanalysis
Exact Sciences is known for its Cologuard test for non-invasive colon cancer screening. They are leaders in early diagnostics. This chart shows the overall short position in the medical diagnostics sector. High short positions in the industry may indicate that investors are concerned about increased competition or changes to the reimbursement system.
Shares shorted by the overall market
Exact Sciences (EXAS) is a leader in early cancer diagnostics, known for its non-invasive test, Cologuard. This chart measures the overall level of fear. When pessimism rises, investors look to EXAS as a "safety net." Cancer screening isn't something to skimp on during a recession. Demand for their tests remains high, as health trumps economic cycles.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Exact Sciences (EXAS)
Exact Sciences is a leader in noninvasive diagnostics and the creator of the Cologuard test. **This chart** measures the reaction to binary events. Successful data from their new "liquid biopsy" test (multi-cancer) could trigger explosive growth and euphoria (above 70). A test failure would send **This chart** into panic mode (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Exact-Sciences-EXAS&v=1772513566660 "RSI 14 indicator chart for the company's stock Exact Sciences (EXAS)")
RSI 14 Market Segment - Medanalysis
Exact Sciences (EXAS) is a "revolution" in diagnostics. Their flagship product is Cologuard, a non-invasive (at-home) colon cancer test. Their business is "convincing" the world to get tested. This metric measures the "temperature" of the sector. It helps us understand: is EXAS oversold due to increased competition or is there a general cooling in the diagnostics sector as a whole?
RSI 14 for the overall market
Exact Sciences (EXAS) is a molecular diagnostics company best known for its noninvasive colon cancer test, Cologuard. This indicator of market risk appetite is important. EXAS is a growth story, dependent on the adoption of its tests. In moments of euphoria, investors believe in the future. In times of panic, they doubt returns and flee unprofitable biotechs.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EXAS (Exact Sciences)
Exact Sciences is a diagnostics company whose flagship product is Cologuard, a noninvasive DNA-based colon cancer screening test. It's a game-changer in oncology diagnostics. This chart shows the analysts' average 12-month target, reflecting their forecasts for Cologuard's adoption rate and progress in developing tests for other cancer types.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EXAS-Exact-Sciences&v=1772513566706 "A chart showing analyst consensus forecasts for the expected stock price. EXAS (Exact Sciences)")
The difference between the consensus estimate and the actual stock price EXAS (Exact Sciences)
Exact Sciences is a molecular diagnostics company. Their flagship product is Cologuard, a noninvasive (stool-based) colon cancer screening test. This chart shows analysts' confidence in the continued widespread adoption of Cologuard and their oncology R&D pipeline. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EXAS-Exact-Sciences&v=1772513566739 "A chart showing the difference between the consensus forecast and the actual stock price. EXAS (Exact Sciences)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Exact Sciences is a leader in early cancer diagnostics, known for its noninvasive colon cancer test, Cologuard. The company is actively developing its liquid biopsy product. This chart shows analysts' overall expectations for the medical testing sector. It reflects whether experts believe the early cancer diagnostic market will boom.
Analysts' consensus forecast for the overall market share price
Exact Sciences is a pioneer in cancer diagnostics. Their flagship product is Cologuard, a noninvasive colon cancer test. Market expectations, as shown in this chart, influence them. During a recession (pessimism), people may visit their doctors less frequently for routine (non-urgent) checkups, which could slow the adoption of their tests.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Exact Sciences
Exact Sciences is a pioneer in early cancer diagnostics. Their flagship product is Cologuard, a noninvasive colon cancer screening test. This chart reflects their explosive growth story. It measures the volume of Cologuard tests performed and market expectations for their future developments in liquid biopsy for other cancer types.
AKIMA Market Segment Index - Medanalysis
Exact Sciences is a leader in non-invasive cancer diagnostics; the company is known for its Cologuard colorectal cancer screening test and is growing in oncologic tests (Oncotype DX). This aggregate metric evaluates companies. The chart shows the sector average. This benchmark: how does Exact Sciences' leadership in early diagnostics differentiate it from the average competitor?
The AKIM Index for the overall market
Exact Sciences is a company that has revolutionized cancer diagnostics. Its flagship product is Cologuard, a noninvasive colon cancer test. This chart, reflecting the market average, provides context. It helps assess how this growth story in the defensive healthcare sector compares to broader macroeconomic trends that impact risk appetite.
